Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Current Quarter	$-0.3	Next Quarter	$-0.31
Current Year	$-1.07	Next Year	$-1.25
QoQ Growth	-3.3%	YoY Growth	-16.8%
3Y EPS CAGR	+20.3%	Target Price	$58.13
Consensus	Buy	Upside	+50.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TERN	$38.52	+4.62%	3.63M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TERN	$38.52	+4.6%	3.63M
3
4
5
6

TERN

TERN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Terns Pharmaceuticals Inc. Data in Excel

Get Terns Pharmaceuticals Inc. Data in Excel